1026471-43-1

Basic information

• Product Name: C₁₉H₁₆N₂O₆S
• CAS NO: 1026471-43-1
• Molecular Weight: 400.412
• Mol File: 1026471-43-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₁₉H₁₆N₂O₆S(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₉H₁₆N₂O₆S(1026471-43-1)
• EPA Substance Registry System: C₁₉H₁₆N₂O₆S(1026471-43-1)

Safety Data

• Hazardous Substances Data: 1026471-43-1(Hazardous Substances Data)

Upstream product

• 128-44-9 saccharin sodium salt 
• 127511-45-9 3-(2-Benzylsulfamoyl-phenyl)-2-cyano-3-oxo-propionic acid ethyl ester 
• 127511-55-1 [2-Benzyl-1,1-dioxo-1,2-dihydro-1λ⁶-benzo[d]isothiazol-(3Z)-ylidene]-cyano-acetic acid ethyl ester 
• 3416-59-9 N-benzylsaccharin 

Relevant articles and documents

Novel Spirosuccinimides with Incorporated Isoindolone and Benzisothiazole 1,1-Dioxide Moieties as Aldose Reductase Inhibitors and Antihyperglycemic Agents

Compounds from two novel series of spirosuccinimides were prepared.Analogs of series 2 possessed a spiro-fused isoindolone moiety while those of series 3 contained a spiro-fused benzisothiazole S,S-dioxide group.These compounds were evaluated as aldose reductase inhibitors (ARI) in vitro by their ability to inhibit glyceraldehyde reduction using a partially purified bovine lens aldose reductase preparation and in vivo as inhibitors of galactitol accumulation in the lens, sciatic nerve, and diaphragm of galactose-fed rats.Many members from the isoindolone series 2,particularly those containing an isoindolone N-methyl moiety, showed good in vitro and in vivo potency.The most potent member, the 6-chloro analog 32, was resolved, and aldose reductase activity was found to reside almost exclusively in the (+)-enantiomer.Compound 32 was approximately equipotent in the sciatic nerve of the galactose-fed rat to other cyclic imide ARI's of similar in vitro activity, namely sorbinil and ADN-138 and also to tolrestat, an acetic acid-based ARI (ED50's 4-8 mg/kg).Compounds from both series, 2 and 3, were also found to lower plasma glucose levels of genetically obese db/db and ob/ob mice with potency similar to that of ciglitazone.However, members from these series failed to lower insulin levels of the ob/ob mouse at the doses tested.